RxDoctor Payments Data

Kenan Sahbaz

Family · Saint Louis, MONPI 1285143545

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,250 of the $14,130 with a category attached, or 79.6%. Optinose US, Inc. accounts for 90.4% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $4,952, more than ten times the $206 reported in 2021. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,130in general payments, 2019–2025

Across 190 payments — averaging $74.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$13K
  • Sanofi$392
  • Regeneron Healthcare Solutions, Inc.$237
  • Jazz Pharmaceuticals Inc.$219
  • GSK$212
  • Axsome Therapeutics, Inc.$132
  • plus $160 from 5 others

What the payments were for

  • Speaking & faculty fees$11,25080%
  • Food & beverage$2,81920%
  • Education$620%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,130 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$151,524
Medicare patients
618
Services billed
3,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate21$18,358
Azelastine Hcl232$5,835
Ipratropium Bromide253$5,694
Epinephrine13$1,830
Mometasone Furoate14$979
Fluticasone Propionate62$895
Omeprazole114$894
Famotidine149$873
Insulin SyringeSyringe And Needle,insulin,1ml24$795
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$264
Methylprednisolone24$190
Prednisone47$138
Mupirocin12$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$12,779$18,35821 claims
Hikma Pharmaceuticals USAEpinephrine$17$1,83013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →